Every October, pink ribbons flood communities, symbolizing awareness of breast cancer’s impact. Yet few know that over four decades ago, a groundbreaking discovery was silenced, altering the course of cancer treatment. In 1977, Dr. Harold W. Manner, Chairman of Loyola University’s Biology Department in Chicago, and his team found that Laetrile—also known as Vitamin B17 or amygdalin—combined with enzymes and vitamin A, caused tumors to shrink in up to 89% of laboratory cases. Manner’s assertion that “cancer is a metabolic problem” challenged conventional approaches, yet his findings were buried.

By 1978, Manner expanded his research to human trials, reporting that 15 women with breast cancer experienced complete tumor regression using the same regimen. These results, if validated, could have offered a non-toxic alternative to mastectomies, chemotherapy, and radiation. Instead, mainstream medicine dismissed his work, cutting funding, rejecting publications, and labeling Laetrile as quackery. The National Cancer Institute selectively highlighted negative studies while ignoring positive data.

The 1977 Congressional hearings on Laetrile marked a turning point. Patients testified to survival stories, but officials branded the therapy “unproven.” Media outlets, including The New York Times, launched an aggressive campaign against Laetrile, publishing 158 articles in 1977 alone that framed it as dangerous. Coverage plummeted afterward, effectively erasing the treatment from public discourse.

Dr. John A. Richardson, MD, had already documented over 6,000 case histories of cancer patients treated with Laetrile, showing tumor regression and improved outcomes. Together with Manner’s research, these findings could have revolutionized oncology. Instead, both were suppressed through ridicule and regulatory barriers.

The consequences are stark: millions of women underwent invasive surgeries and toxic therapies while a natural alternative was ignored. Since 1977, an estimated two million American women have died from breast cancer, with critics arguing that Laetrile’s potential could have saved hundreds of thousands.

The article highlights the suppression of Dr. Manner’s work and the broader systemic resistance to alternative treatments. It calls for transparency, urging a reevaluation of medical history and the prioritization of patient autonomy over institutional interests.